AGE–RAGE–DIAPH1 Axis Drives Diabetic Myocardial and Neuronal Injury via Carbonyl Stress in Type 2 Diabetes
Background
In obesity and type 2 diabetes mellitus (T2DM), chronic systemic inflammation and insulin resistance drive progressive metabolic dysfunction. The receptor for advanced glycation end-products (RAGE) acts as a critical hub, integrating multiple metabolic and inflammatory signals. While initially known for binding advanced glycation end-products (AGEs), RAGE also interacts with other ligands like HMGB1 and S100 proteins. This activation promotes oxidative stress and inflammatory responses, contributing to vascular dysfunction and tissue remodeling, particularly in vulnerable organs like the heart and neurons.
Study Design
This comprehensive review synthesizes current literature on the AGE–RAGE–DIAPH1 axis in type 2 diabetes mellitus (T2DM) and metabolic dysfunction. It explores the molecular mechanisms by which advanced glycation end-products (AGEs) and their receptor (RAGE), in conjunction with diaphanous-related formin 1 (DIAPH1), contribute to chronic inflammation and tissue damage. The review focuses on the progression from carbonyl stress to specific complications like diabetic myocardial and neuronal injury, highlighting the translational relevance of targeting this signaling pathway. The authors discuss the role of RAGE's cytoplasmic domain interaction with DIAPH1 in coupling cell surface events to intracellular changes and downstream pathways.
Results
The review highlights that RAGE activation, triggered by AGEs and other ligands such as HMGB1 and S100 proteins, significantly promotes oxidative stress and inflammatory responses. This sustained pathogenic activity is critical for vascular dysfunction and tissue remodeling across various organs. Signal propagation through RAGE is dependent on its interaction with diaphanous-related formin 1 (DIAPH1), which couples extracellular signals to intracellular architectural changes and downstream pathways. This mechanism is particularly detrimental in tissues highly sensitive to chronic metabolic stress, including the heart and neurons, leading to diabetic myocardial and neuronal injury. The authors emphasize the translational relevance of this axis:
Small-molecule antagonists that interrupt RAGE–DIAPH1 signaling have shown promise in reducing diabetic complications in experimental models, underscoring its potential as a therapeutic target.
Key Findings
- The AGE–RAGE–DIAPH1 axis is central to metabolic dysfunction and chronic inflammation in type 2 diabetes.
- RAGE activation by AGEs, HMGB1, and S100 proteins promotes oxidative stress and inflammatory responses.
- The RAGE–DIAPH1 interaction is crucial for signal propagation, linking cell surface events to intracellular changes.
- This axis contributes to vascular dysfunction, tissue remodeling, and specifically diabetic myocardial and neuronal injury.
- Small-molecule antagonists targeting RAGE–DIAPH1 signaling show promise in reducing diabetic complications in models.
Why It Matters
Understanding the AGE–RAGE–DIAPH1 axis provides a crucial mechanistic link between metabolic stress, inflammation, and the development of severe complications in type 2 diabetes. This review reinforces the idea that T2DM is more than a glycemic disorder, highlighting the pervasive tissue damage driven by chronic inflammation. Targeting the RAGE–DIAPH1 interaction represents a promising therapeutic strategy to mitigate diabetic myocardial and neuronal injury, moving beyond traditional glucose-centric treatments. The development of small-molecule antagonists interrupting this signaling pathway could lead to novel interventions that protect vulnerable tissues and improve long-term outcomes for individuals with T2DM and metabolic dysfunction.
type 2 diabetes
metabolic dysfunction
rage
diaph1
ages
inflammation